Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00954278 | Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 24 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01478685 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 169 | CelgeneINDUSTRY | 4 | Nov 12, 2019 | clinicaltrials |
| NCT01545947 | Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 76 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | completed | Phase 1 | 128 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT00894127 | Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer | completed | Phase 1 / Phase 2 | 128 | Biomoda Inc.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 28 | ACEA Therapeutics, Inc.INDUSTRY | 3 | Oct 29, 2019 | clinicaltrials |
| NCT03780010 | Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | completed | Phase 1 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 0 | Oct 28, 2019 | clinicaltrials |
| NCT02836834 | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | terminated | Phase 1 / Phase 2 | 3 | University of FloridaOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT03101839 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 2 | Oct 4, 2019 | clinicaltrials |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00037817 | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02603003 | the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs(CTC-TCM-FZ) | completed | Phase 1 | 218 | Shanghai University of Traditional Chinese MedicineOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02425748 | Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02845856 | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03983928 | Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer(NSCLC) | withdrawn | Phase 1 | 0 | Benjamin Movsas, M.D.OTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT01433172 | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | completed | Phase 1 / Phase 2 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT02128724 | Palliative Thoracic Radiotherapy Plus BKM120(BKM120) | completed | Phase 1 | 21 | University of OxfordOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT03510611 | A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. | completed | Phase 1 | 24 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03536481 | Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers | completed | Phase 1 | 74 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02094950 | Acupuncture Feasibility Trial for Dyspnea in Lung Cancer | completed | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01837329 | Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer | completed | Phase 1 | 26 | University of RochesterOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02914990 | Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients | completed | Phase 1 | 36 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03366064 | Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(Medi-NK) | completed | Phase 1 | 5 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02630186 | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | terminated | Phase 1 / Phase 2 | 3 | Clovis Oncology, Inc.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01543672 | Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously(VOLUMES) | completed | Phase 1 / Phase 2 | 62 | The Netherlands Cancer InstituteOTHER | 4 | Jun 27, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT00714246 | Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 6 | Milton S. Hershey Medical CenterOTHER | 1 | Jun 24, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 15, 2019source: clinicaltrials